Frist Cressey Ventures led a $20m Series A funding round in Aradigm.

Frist Cressey Ventures, a venture capital firm, led a $20m Series A funding round in Aradigm, a benefits platform for cell and gene therapies, with participation from Andreessen Horowitz and Morgan Health. “Cell and gene therapies have extraordinary potential to transform lives, but the fragmented way we pay for and deliver care in the U.S. threatens access to them. What we have built is a new kind of payment and delivery model that breaks down barriers to these life-saving therapies,” William Shrank, Aradigm CEO and Co-Founder.